Medical radiation should be used appropriately and with a dose as low as reasonably achievable. Dose monitoring technologies have been developed that automatically accumulate patient dose indicators, providing effective dose estimates and patient-specific dose histories. Deleterious radiation related events have prompted increased public interest in the safe use of medical radiation. Some view individualized patient dose histories as a tool to help manage the patient dose. However, it is imperative that dose monitoring technologies be evaluated on the outcomes of dose reduction and effective patient management. Patient dose management needs to be consistent with the widely accepted linear no-threshold model of stochastic radiation effects. This essay reviews the attributes and limitations of dose monitoring technologies to provoke discussion regarding resource allocation in the current fiscally constrained health care system.
Radiation is believed to be a weak carcinogen and the amount used in medical imaging should be as low as reasonably achievable (ALARA). With technological improvements and innovation, new dose monitoring technologies are able to: 1) automatically accumulate and sort modality/equipment based dose indicators; 2) provide estimates of effective dose; 3) compile patient dose histories; and 4) provide the medical physics and radiology community with additional quality control tools to further enforce ALARA principles. In diagnostic radiology, current standards for new equipment require the transmission of modality specific dose indicators to picture archiving communication systems (PACS) as a component of the permanent patient imaging medical record and enable radiologists to monitor appropriate dose. Deleterious radiation related events have increased public interest regarding the safe use of radiation in medical imaging, resulting in some jurisdictions passing laws requiring the recording of dose into the patient's medical record [1] . The radiology community must practice ALARA and explore new technologies to enable dose reduction, including automated dose registries. The introduction of this new technology needs to be assessed to ensure we use the information in a clinically appropriate manner and under the constraints of the linear no-threshold (LNT) model of radiation related stochastic risk. It is imperative that dose monitoring technologies are evaluated on their merit with regards to aiding dose reduction and appropriate patient management, rather than a reaction to media or public pressure.
To this aim, we present a review of dose monitoring technology and the utility of patient-specific dose histories. We hope this review will assist medical imaging departments in rationally assessing the purchase and implementation of cumulative dose tracking technologies.
Diagnostic Reference Levels: Automated Sorting of Scanner/Patient Data
Diagnostic reference levels (DRLs) are an established, effective technique to set guidelines for imaging radiation dose [2e5]. Comparative analysis of DRL data relies on the procurement of patient doses for standard sized patients (70 AE 20 kg), or other specific patient size metrics. The acquisition of these data is typically performed by a medical physicist or the site radiation safety officer. To effectively establish a DRL for a given scanner type and examination, data are required from multiple sites for the same scanner type (eg, make, model, available dose reduction technologies). It is standard practice to collect at least ten samples from each clinically indicted examination and patient size category to get an estimate of the dose distribution [4, 6] . If practical, collecting more than 10 samples is recommended and will give a better estimate of the true dose distribution. The 75th percentile of the dose distributions for a given exam, specified patient size or weight range, and equipment type, is typically stated as the DRL. Doses above this level require investigation by the medical imaging team, including radiologists, medical physicists, and radiation technologists, to decide what action, if any, is required.
When performed widely, the DRL approach to dose reduction is effective. UK reference levels have been reduced by 10% since 2005 and by over 50% since inception in the mid-1980s [4] . While this reduction is not solely due to applying DRLs (other dose reduction technologies such as the transition to flat panel detectors instead of film have also played a role), DRLs were pivotal in narrowing the ranges of doses used for particular examinations [4] .
Although DRL methodology is well established, it has several limitations:
1. Data collection and analysis are time consuming. 2. The data are prone to error, both systemic (ie, technologist misinterpreting parameters) and random (ie, including appropriate high dose data due to implants). 3. The data are only a snapshot and captures a limited number of exams performed.
Medical informatics has enabled automated solutions to both collection and analysis of DRL data. Some commercially available products include: American College of Radiology e Dose Index Registry [7] , General Electric e DoseWatch [8] , Bayer e Radimetrics [9] , and popular free systems (General Radiation Observation ToolKit [10] and Radiance [11] ) are also available. More recently, Radiology Information Systems have incorporated the ability to collect DICOM Structured Reports to record radiation utilization within a patient's Electronic Medical Record.
The strengths and limitations of specific software are beyond the scope of this essay. We suggest that medical imaging leadership at each hospital or health region analyze the costs and benefits of implementation of a traditional DRL method compared to an automated system.
The natural consequence of automated dose registries is the establishment of patient-specific dose history databases.
Patient-Specific Dose History Databases
Patient-specific dose history tracking software must be carefully examined as a potential clinical tool. A short list of considerations includes:
1. Completeness of medical dose history. 2. Accuracy of effective dose calculations. 3. Clinical utility of patient specific dose histories. 4. Effective use of financial resources to implement a dose registry.
Completeness of Dose History
Radiation exposure is part of many aspects of daily life. Patient-specific cumulative medical dose histories need to capture all instances in order to be complete. Besides medical radiation from hospitals and clinics, additional sources of individual dose that might need to be considered include dental exams and chiropractic x-rays. There are many technical and legal hurdles to solve in order to securely and ethically share patient information between public and private enterprises, hospitals, health regions, provinces, and countries.
Accuracy of Effective Dose Calculations
In order to record and compare an individual's effective dose from various sources, the unit mSv has been developed. For a review of dose units and indicators please see Thakur et al [12] . A simple first pass is to take a dose indicator, such as kerma area product (KAP) for radiography and fluoroscopy or dose-length product (DLP) for computed tomography (CT), and apply a conversion factor to get effective dose in mSv (see Definitions in Appendix 1). For more accurate patient-specific effective dose measurements, each exam should be assessed individually, taking into account patient size and age, tube voltage, beam quality, and precise volume of organs irradiated. In this case, accuracy begets complexity.
The accuracy and long-term storage of patient effective dose is further complicated because our understanding of tissue sensitivity is constantly improving. For example, longer term follow-up of radiation exposed subjects led the International Commission on Radiological Protection to revise certain tissue sensitivities in their 2007 report [13] . Breast tissue is now considered more radiation sensitive and gonadal tissue less sensitive [13] , resulting in effective dose estimates prior to the ICRP 2007 recommendations differing from those calculated today. Furthermore, use of effective dose to estimate risk can lead to significant over/under estimate of risk. For example, Ivanov et al [14] demonstrated in an example CT study that use of effective dose instead of organ absorbed dose can under estimate risk by a factor of 1.73. Reporting effective dose in mSv is not precisedtissue absorbed dose needs to be recorded and patient cumulative effective dose needs to be updated as these tissue weighting factors change with time. Furthermore, effective dose might not be enough because it does not include gender or age, which are important components of the recently developed concept of radiation risk index. This index accounts for the fact that some tissue is at greater risk when exposed at a younger age, because the cells are more likely to divide in the future and have a longer life span to do so [15] .
Clinical Utility of Patient-Specific Dose Histories
There are 2 types of biological effects from radiation, stochastic effects and tissue reactions (previously described as deterministic effects). Stochastic effects are malignant disease and heritable effects for which there is no threshold and the probability of occurrence increases with increasing dose but whose severity is independent of total dose. Tissue reactions are the result of injury in populations of cells, characterized by a threshold dose and an increase in the severity of the reaction as the dose is increased further [13] .
Similar to rolling dice, according to the LNT model there is no buildup effect for each event of stochastic risk for an individual. Previous exposures have either induced a stochastic effect, or not. Assuming there has been no effect from previous exposures, then a subsequent exposure has no greater risk than a first diagnostic examination given the same patient age and tissue absorbed dose. Similarly, if there has been a stochastic effect that has not been detected yet, the damage has already been done and a subsequent exposure will not exacerbate the initial injury, but instead has the same probability of creating a new one. Indeed, most experts will find it counterintuitive that Durand [16] developed a simple mathematical proof using the standard LNT model of stochastic risk that after the initial scan relative risk for each successive scan declined minimally. Durand's proof is based on applicability of the widely accepted LNT model and our current understanding of long-term radiation induced effects. The LNT model itself is controversial, but it might be the best we can do given the weak induction effect of radiation and long latency period after exposure [17] . Other risk models exist and are beyond the scope of this essay.
Databases of patient-specific cumulative dose could allow physicians to assess a patient's dose history before requesting a diagnostic exam. However, access to such histories without sufficient understanding of the probabilistic nature of the risk associated with effective dose could cause a physician to forego requesting the most appropriate exam [18] . Put simply, the frequency and amount of dose used from previous diagnostic exams should not discourage a clinician from requesting a diagnostic examination if it is clinically appropriate, nor discourage a radiologist from authorizing the examination. This point cannot be understated. Pandharipande et al [19] showed that most radiologists when presented with a patient dose history, made decisions contradicting the LNT model, deciding to forego the most appropriate exam and favor a lower or no dose alternative. This, in turn, may increase patient risk from the disease process or misdiagnosis.
Patients who receive frequent examinations may be receiving inappropriate care, harboring a disease process not detectable by imaging, or frequent diagnostic examinations may have been required as an appropriate standard of care. Determining which, if any, of these apply can be done more directly without access to individual cumulative dose histories. Simply reviewing institutional or provincial PACS records will quickly identify recurrent imaging requests. Improving exam appropriateness is better addressed through requesting physician education and radiologist vetting than individual cumulative dose histories. If only appropriate exams are performed, this can also aid in reducing population dose.
Analogy
An analogy to radiation associated stochastic risk can be found in the accident risk from driving to work. Similar to radiation exposure, every trip is associated with a small but significant accident event risk. Using the dose registry approach, if someone has an extensive commuting record, should they stop driving to work after passing a threshold number of kilometers?
All drivers share the cumulative commute risk. If everyone drives in a manner that makes their individual risk ALARA, population risk can be reduced. Common driving practices (speed limits, stop signs, rules of the road) are essentially driving ALARA principles. Further focus on ALARA, such as driving slowly if road conditions are poor, regardless of the posted limit, further reduces population risk.
The key point in this analogy is medical radiation risk is often not viewed in the same fashion as driving risk, even though in both cases, previous risk has no link to future risks based on the LNT model of radiation risks.
When Is a Patient Specific Dose History Useful?
There are some cases where patient effective dose needs special management. For example, a congenital condition such as scoliosis or an ateriovenous malformation could require frequent follow-up diagnostic imaging for many years. A genetic disorder might make a patient more sensitive to the effects of radiation (ie, ataxia-telangiectasia, Li-Fraumeni syndrome, Fanconi anemia, or dyskeratosis congenita). Dose management in these cases should be proactive, with a diagnosis/monitoring imaging approach planned from the beginning instead of looking backwards at the patient's dose history each time a clinician considers the next exam. And whenever appropriate and in line with imaging or disease surveillance objectives, alternate imaging modalities might be appropriate, such as for example, using ultrasound or MR enterography for Crohn's disease in children.
It is recognized that cumulative dose histories would be useful for epidemiological studies of the effects of low dose radiation. Epidemiological and experimental studies of stochastic effects for low dose radiation (<100 mSv) have large uncertainties, and established effects at low doses are linearly extrapolated from high dose exposures (>500 mSv) to low dose exposures [13] . Unfortunately, the major limitation in stochastic risk estimates for low doses is that acceptable epidemiological studies that enroll enough individuals to assess such a small risk are very expensive and take a long time, perhaps the length of a working career or 2. A cumulative dose history would be useful for such a long-term study, but it would have to be performed on a national, or perhaps international, scale in order to have sufficient statistical power.
Short-term dose histories are of the utmost importance in interventional fluoroscopy [20] and CT perfusion [21] cases. Tissue reactions have a threshold and the deleterious effects increase with dose. Tissue can heal after the exposure, but because it takes time to heal, additional exposures to the same anatomical region within 60 days should be considered additive for radiation safety purposes [22] . A peak skin dose of 2000-5000 mGy can cause transient erythema, an inflammation of the capillary network within skin tissue, within 2 weeks, and possible epilation between 2-8 weeks.
Radiation dose above this threshold will lead to more severe tissue reactions (ie, dry or moist desquamation from 10 000-15 000 mGy taking 2-8 weeks to manifest, or radiation induced skin burns and subsequent skin necrosis for peak skin doses >15 000 mGy taking 6-52 weeks to develop) [23] .
Cases where peak skin dose might exceed 2000 mGy include only a small subset of the patient population, so a simple low-tech method of tracking patient skin dose will suffice. The first step is identifying patients who may have exceeded a threshold, and sending these patients home with an information sheet outlining what type of radiation effect might occur, where, and what dose indicator triggered the handout. Patients should then be asked to notify any future interventionalists (within 60 days) of previous, recent exposure(s). They could simply bring this information sheet with them to the appointment. If they are an in-patient, this sheet could be put in the patient's chart. Steele et al [23] describes an excellent instance of this type of radiation quality improvement program and provides an example of a post-procedure information sheet for patients if they might experience a tissue reaction. The NCRP168 report recommends the following dose indicator values be used to trigger patient follow-up: reference air kerma >5000 mGy, KAP >500 Gy cm 2 , and fluoroscopy time >60 min, in order of preference [24] .
Effective Use of Financial Resources to Implement a Dose Registry
Given the budgetary constraints of the health care system, is it cost effective to track individual cumulative dose? If a patient-specific cumulative dose history has much lower value in the clinical management of an individual patient compared to improving examination appropriateness, is not the money better spent on clinically validated order entry appropriateness software? The answer of course, depends on relative cost effectiveness, which must be widely assessed prior to purchase. Competing dose reduction approaches of establishing and monitoring DRLs, or upgrading dose reduction technologies must also be considered.
Conclusion
Long-term patient-specific dose histories are useful for epidemiological studies of stochastic effects to populations and short-term histories help manage and reduce tissue reactions to individuals. Short-term records of peak surface dose in interventional fluoroscopy and CT perfusion examinations are useful for identifying procedures planned to be performed on the same anatomical region within 60 days, where the surface dose should be considered additive for tissue reactions (deterministic effects). Knowledge of these anatomic sites allow interventionalists to make best efforts to avoid irradiating previously exposed skin surfaces in order to prevent, or not further exacerbate, tissue reactions. A cumulative effective dose history provides no clinical decision making benefit to an individual patient since the frequency and number of previous diagnostic exams should not discourage a clinician from requesting or a radiologist performing a clinically appropriate exam. Before investing in the purchase and maintenance of patient specific cumulative dose tracking, a rational assessment with comparison to more cost-effective dose reduction strategies need to be made.
The Canadian Association of Radiologists Radiation Protection Working Group
The Canadian Association of Radiologists (CAR) Radiation Protection Working group is made up of radiologists and medical physicists spread throughout Canada. This essay provides a consensus opinion of the working group regarding the use of patient-specific cumulative dose tracking.
